Skip to main content
Fig. 1 | Annals of Clinical Microbiology and Antimicrobials

Fig. 1

From: Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Fig. 1

CRP, SARS-CoV-2 PCR testing results and timeline of therapies in Cases 1 (A) and 2 (C). Light blue squares represent positive and orange squares negative swab PCR results. Dark blue and green boxes demonstrate treatment episodes of remdesivir (RDV) and dexamethasone (DEX) respectively. Purple arrow represents convalescent plasma (CP) administration (given over two days) and red arrows casirivimab and imdevimab (REGN-COV2) administration. CT thorax appearances prior to RGN therapy in Cases 1 (B) and 2 (D) demonstrating pneumonitis

Back to article page